Lupin announced the launch of Azilsartan Medoxomil Tablets, 40 mg and 80 mg, in the United States following approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA). According to reports from CNBC TV18, the product is bioequivalent to Edarbi of Azurity Pharmaceuticals and is indicated for the treatment of hypertension in adults to lower blood pressure. Lupin stated it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market. The launch was officially announced on June 17, 2026, positioning the company to capitalize on the market before other generic competitors enter.
According to IQVIA MAT April 2026 data as reported by CNBC TV18, Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the United States during the 12 months ended April 2026. This represents a significant market opportunity for Lupin's generic version of the hypertension treatment, positioning the company to capture a portion of the established market for blood pressure management medications. The launch targets a $53.5 million therapeutic segment in the cardiovascular space, representing a strategic move into high-margin chronic care participation rather than volume-focused generic products. The introduction of this product strengthens Lupin's portfolio in the cardiovascular therapy area, where the company holds a strong position across multiple segments including respiratory, anti-diabetic, and anti-infective therapies.
The Azilsartan launch builds on Lupin's recent momentum in the US generics market, following approval on May 29 for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets, a generic version of Sutab tablets marketed by Azurity Pharmaceuticals. As reported by CNBC TV18, Lupin was the exclusive first-to-file applicant for that product as well, making it eligible for another 180-day exclusivity period. The tablets will be manufactured at the company's facility in Nagpur. In the last 90 days, Lupin has received USFDA approval for Mirabegron Extended-Release Tablets and finalized a partnership for complex injectables, with the company reporting 12% YoY growth in US revenue during the previous quarter. The company operates 15 manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals across more than 100 markets.
Lupin's entry into the $53.5 million Azilsartan Medoxomil segment deepens its presence in the cardiovascular segment, which is a key pillar of its chronic therapy focus aimed at achieving sustainable margins in the US market. The launch is expected to be margin-accretive for Lupin's US operations and strengthens the balance sheet by utilizing existing US distribution infrastructure for high-volume generics. The US generics business accounts for approximately 35% of Lupin's global sales, making this launch strategically important for the company's overall performance. Lupin's ability to consistently roll out generic versions of chronic care drugs reinforces its competitive moat in the global generic landscape, with the company joining a selective group of generic players for this molecule, enhancing its pricing leverage and positioning for future expansion into other therapeutic areas.
Despite the positive product launch news, shares of Lupin ended at ₹2,276.50 on the NSE on June 17, down 0.06% from the previous close, according to CNBC TV18. The stock movement suggests that while the generic drug approvals represent significant market opportunities, investors may be focusing on other factors affecting the pharmaceutical company's stock performance. However, the launch signals a robust product cycle for FY27, with positive bias driven by US portfolio expansion into the $53.5 million segment and consistent USFDA approval momentum in the last 60 days. The company's focus on chronic segments like hypertension allows for more predictable revenue streams compared to acute therapies, with recent regulatory shifts emphasizing supply chain security favoring established players like Lupin with multi-site manufacturing capabilities.
